Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12730566 | 0.91 | ADAM17 (0.55) | PTGDR2ADAM17GAANPSR1MEN1 | |
| SCHEMBL12708180 | 0.83 | ADAM17 (0.71) | ADAM17GAAKDM4EMMP2MMP8 | |
| SCHEMBL12731180 | 0.82 | PTGDR2 (0.42) | PTGDR2ADAM17GAAKDM4ENPSR1 | |
| SCHEMBL19215172 | 0.82 | KDM4E (0.48) | PTGDR2GAAKDM4EMEN1PKM | |
| SCHEMBL8324207 | 0.81 | GAA (0.68) | ADAM17GAANPSR1MEN1PKM | |
| SCHEMBL12730541 | 0.79 | ADAM17 (0.39) | PTGDR2ADAM17GAANPSR1MEN1 | |
| SCHEMBL8334734 | 0.77 | KDM4E (0.57) | ADAM17GAAKDM4EMEN1KMT2A | |
| SCHEMBL8330234 | 0.76 | ADAM17 (0.74) | ADAM17GAAKDM4EMMP2MMP8 | |
| SCHEMBL3528983 | 0.74 | MAPT (0.50) | PKMALDH1A1 | |
| SCHEMBL8334686 | 0.72 | ADAM17 (0.71) | ADAM17GAANPSR1MEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919520-B2 | Inhibitors of tace | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090176782-A1 | INHIBITORS OF TACE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7485664-B2 | Inhibitors of TACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-03 | — | — | US | disclosed |
| WO-2004056766-A1 | INHIBITORS OF TACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176782-A1 | INHIBITORS OF TACE | HDGF, ADAM17, PCSK9 | PTGDR2 2935/4885ADAM17 2/4885GAA 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.